This is a ready-to-use risk assessment for identifying and scoring the stability and process risks a formulation development program faces, tied explicitly to the modality’s actual dominant degradation mechanism rather than a generic excipient checklist. Replace every <<FILL: ...>> placeholder with your own specifics. A worked filled specimen follows. Verify each cited reference against the current source before you rely on it.
Document control header
| Field | Entry |
|---|---|
| Document title | Formulation Stress Risk Assessment for <<FILL: product>> |
| Document number | <<FILL: e.g. FRA-2026-05>> |
| Version | <<FILL>> |
| Modality | <<FILL: protein / oligonucleotide (naked or LNP) / cell / viral vector (AAV)>> |
| Assessment owner | <<FILL>> |
1. Purpose
This assessment identifies and scores the stresses most likely to degrade <<FILL: product>> given its modality’s actual failure mode, so mitigation effort and formulation development time go to the risks that matter most for this specific molecule or cell product, not to a generic list borrowed from a different modality.
2. Scope
| Dimension | Decision |
|---|---|
| Product / modality in scope | <<FILL>> |
| Development stage | <<FILL: e.g. early formulation screening / late-stage lock>> |
| Out of scope | <<FILL: e.g. long-term storage stability, covered under a separate stability protocol>> |
3. Methodology and scoring scales
Score each identified stress on severity (impact on product quality or function if the stress is not controlled) and likelihood (probability of occurrence under realistic manufacturing, shipping, and clinical handling conditions). Risk priority is severity multiplied by likelihood; a score of 12 or higher, on a 1 to 5 scale for each factor, requires a documented mitigation before formulation lock, not just a note for later.
| Score | Severity meaning | Likelihood meaning |
|---|---|---|
| 5 | Loss of critical quality attribute or function, patient safety impact possible | Expected to occur under normal handling |
| 4 | Significant quality impact, likely out-of-specification result | Likely under realistic handling variation |
| 3 | Moderate quality impact, may still meet specification with margin loss | Possible under a realistic but less common scenario |
| 2 | Minor quality impact, unlikely to affect specification | Unlikely, requires an uncommon combination of conditions |
| 1 | Negligible quality impact | Rare, requires an atypical failure |
4. Modality-specific stress assessment
Name the actual dominant failure mode for this modality before scoring; do not carry forward a stress category from a different modality’s assessment by default.
| Stress | Modality-typical mechanism | Severity | Likelihood | Risk priority | Mitigation |
|---|---|---|---|---|---|
| Interfacial aggregation (air-liquid, container-liquid) | Protein | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. surfactant selection>> |
| Oxidation / deamidation | Protein | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| Hydrolytic backbone cleavage | Oligonucleotide | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. pH and buffer control>> |
| Duplex destabilization | Oligonucleotide (double-stranded) | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| LNP particle size / encapsulation efficiency drift | Oligonucleotide (LNP-formulated) | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. controlled shear during mixing>> |
| Osmotic / mechanical membrane damage | Cell | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. cryoprotectant selection>> |
| Intracellular ice formation | Cell | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. controlled cooling rate>> |
| Delayed apoptosis (post-thaw) | Cell | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. functional potency readout beyond viability>> |
| Cryoprotectant toxicity at infusion | Cell (DMSO-based) | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. reduced-DMSO or DMSO-free alternative>> |
| Siliconization particulate risk (high concentration) | Protein, high-concentration PFS | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. baked-on/cross-linked silicone method>> |
| Capsid rupture / genome (ssDNA) leakage on freeze-thaw | Viral vector (AAV) | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. low-level nonionic surfactant, cryoprotectant, reduced buffer concentration>> |
| Non-specific surface adsorption / titer loss | Viral vector (AAV), especially low concentration | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL: e.g. low-level nonionic surfactant, low-adsorption contact materials>> |
<<FILL: any product-specific stress not listed above>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
5. Residual risk
For every risk priority scored 12 or higher, state the residual risk after mitigation and who accepted it.
| Stress | Risk priority before mitigation | Mitigation applied | Risk priority after mitigation | Residual risk accepted by |
|---|---|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
6. Approval
| Role | Name | Signature | Date |
|---|---|---|---|
| Assessment author | <<FILL>> | ||
| Analytical Development | <<FILL>> | ||
| Quality Assurance | <<FILL>> |
7. References
ICH Q5C, Quality of Biotechnological Products: Stability Testing. ICH Q9(R1), Quality Risk Management. ICH Q8(R2), Pharmaceutical Development.
Confirm the current version of each reference before issue.
8. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen
Extract from a risk assessment for Acme Therapeutics’ ATX-CT7, an autologous CAR T-cell product moving from early development into cryoformulation lock.
| Stress | Severity | Likelihood | Risk priority | Mitigation |
|---|---|---|---|---|
| Intracellular ice formation during freeze | 5 | 3 | 15 | Controlled cooling rate defined by thermal characterization; ice nucleation step added to the cooling ramp |
| Delayed apoptosis (post-thaw) | 5 | 3 | 15 | Functional potency readout added at 4 and 24 hours post-thaw, not viability alone, per the freeze-thaw study protocol |
| Cryoprotectant toxicity at infusion | 4 | 2 | 8 | DMSO concentration set at the lowest level shown to preserve function; patient tolerability rationale documented |
| Osmotic membrane damage during formulation buffer exchange | 3 | 2 | 6 | Gradual, staged buffer exchange rather than a single-step dilution |
Two risks scored 12 or higher and each carries a documented mitigation traced to a specific study, the ice-nucleation cooling profile and the added functional potency readout, rather than a generic note to “monitor closely.”
Common inspection findings this assessment prevents
- A risk assessment that reuses a generic, non-modality-specific stress list, missing the mechanism that actually threatens this product.
- A high risk-priority stress with no documented mitigation, or a mitigation with no connection to a specific study or protocol.
- Severity and likelihood scored without a stated rationale, making the score impossible for a reviewer to evaluate independently.
- A residual risk accepted with no named accepter or date.
How to adapt this assessment
- Set your document number, product, and modality in the header.
- In section 4, remove stress rows that do not apply to this modality and add any product-specific stress not already listed; do not leave irrelevant rows unscored.
- Score every row with a stated rationale, not a bare number.
- Trace every mitigation for a risk priority of 12 or higher to a specific study, protocol, or design change, not a general assurance.
- Confirm every reference in section 7 against the current published version before issue.